Invasive cervical cancer is very highly correlated with the presence of high-risk human papillomavirus (HPV) types 16 and 18. Two viral proteins, E6 and E7, act in concert to subvert growth control of infected cells by inactivating the tumor suppressor proteins, p53 and Rb, respectively. E6 is thought to abrogate p53 function by stimulating its degradation via ubiquitin-mediated proteolysis in a reaction requiring E6AP (E6-Associated Protein). Here we evaluate the in vivo role of E6AP in p53 degradation in normal and HPV-infected cell types using antisense phosphorothioate oligodeoxynucleotides (S-ODNs). This study shows that reduction of E6AP in vivo in high-risk HPV-infected cells leads to an elevation of p53, con®rming the function of E6AP predicted by in vitro experiments. Further, we demonstrate that reduction of E6AP in normal cells has no eect on p53 levels, indicative of an E6AP-indpendent mechanism for p53 degradation. These experiments show that inhibition of intermediate proteins in the ubiquitin-mediated proteolysis pathway (ubiquitin-conjugating enzymes or associated recognition proteins) can result in speci®c inhibition of substrate degradation. We propose that modulation of p53 levels by elimination of E6AP function may have therapeutic potential for cervical cancer.
Introduction
The tumor suppressor protein p53 is mutated or deleted in about half of all human tumors (Harris and Hollstein, 1993) . However, certain tumor types retain a wild-type p53 gene and appear to abrogate p53 function in a non-mutational way. Examples of such tumors are soft tissue sarcomas and cervical carcinomas caused by infection with the high-risk human papilloma viruses. Soft tissue sarcomas frequently overexpress the oncogene product mdm2, which binds to and inactivates p53 (Landanyi et al., 1993) . Nearly 90% of all cervical carcinomas harbor human papillomaviruses (HPV) types 16 and 18 (zur Hausen, 1987) ; many of these retain a wild-type p53 gene. These viruses express the oncoproteins E6 and E7 in cervical cancers (Stremlau and zur Hausen, 1985) and derived cell lines (Yee et al., 1985) . Both E6 and E7 are required for transformation of primary human keratinocytes (MuÈ nger et al., 1989) . High-risk HPVs subvert growth control of cells through the binding and inactivation of key cellular regulatory proteins by E6 and E7. The E7 protein contributes to transformation by functionally inactivating Rb, a tumor suppressor gene (Vousden, 1994) . E6 has been shown to bind p53 and stimulate its degradation in vitro through a ubiquitin-dependent pathway (Schener et al., 1990) . In dierent genetic contexts, deletion or inactivation of p53 may contribute to tumorigenesis by either loss of growth arrest following DNA damage (White, 1994) or inhibition of apoptosis (Lowe et al., 1993a,b; Morgenbesser et al., 1994; Symonds et al., 1994) . For example, in Rb wildtype cells, elevated p53 induces the transcription of the universal cdk inhibitor, p21, leading to growth arrest . However, in Rb-de®cient cells, elevation of p53 leads to apoptosis Morgenbesser et al., 1994; White, 1994) . Reduced apoptotic potential resulting from loss of p53 function may contribute to the refractory response of cervical cancer to conventional chemotherapeutic regimens (Lowe et al., 1993a) .
The conjugation of ubiquitin to protein substrates is a multi-step process (Jentsch, 1992) . In an initial ATPrequiring step, a thioester is formed between the Cterminus of ubiquitin and an internal cysteine residue in the ubiquitin activating enzyme, E1. Activated ubiquitin is then transferred to a speci®c cysteine on one of several ubiquitin-conjugating enzymes (UBCs or E2s). Finally, these UBCs donate ubiquitin to protein substrates that are subsequently degraded by the multiprotein protease complex called the proteasome. Substrates are recognized either directly by a UBC or by associated recognition proteins, the E3 proteins, also called ubiquitin ligases. Ubiquitin ligases often act enzymatically as the last member in the cascade of thioester containing enzymes, ultimately donating ubiquitin to the protein that is destined for degradation.
Most of the key components of the E6-dependent p53 degradation pathway have been characterized in vitro (Huibregtse et al., 1991 (Huibregtse et al., , 1993a Rolfe et al., 1995; Schener et al., 1993 Schener et al., , 1994 Werness et al., 1990) . Various related ubiquitin-conjugating enzymes have been demonstrated to be involved in the ubiquitination of p53 (Rolfe et al., 1995; Schener et al., 1994) . They function by donating ubiquitin to E6AP (Rolfe et al., 1995; Schener et al., 1995) . Ubiquitinylated E6AP and E6 then act together as a ubiquitin protein ligase to transfer ubiquitin to p53, thereby¯agging it for degradation by the proteasome (Rolfe et al., 1995; Schener et al., 1995) .
Because E6AP has been shown in vitro to be required for E6-dependent p53 degradation, we reasoned that elimination of E6AP activity in vivo should lead to elevated p53 and a lowered threshold for p53 mediated apoptosis. We previously provided indirect in vivo evidence for the involvement of E6AP in the E6-dependent degradation of p53 (Rolfe et al., 1995) . Here we demonstrate the direct in vivo importance of E6AP in controlling p53 levels in HPV-infected cells using three independent antisense and three control S-ODNs. Further, we provide evidence that indicates E6AP may not be involved in the turnover of p53 in non-HPV-infected cells. These results suggest that inhibitors of E6AP could lead to increased spontaneous apoptosis and heightened sensitivity to DNA-damaging agents via p53-dependent apoptosis in high-risk HPV-infected cells.
Results

Antisense inhibition of E6AP in HeLa
Antisense S-ODNs targeting three distinct regions of the E6AP mRNA and the corresponding reversed control S-ODNs (Table 1) were introduced individually by lipofection into the HPV18 positive HeLa cell line. Within 12 ± 24 h post-lipofection, the level of E6AP protein in the cells decreased in the presence of each of the antisense S-ODNs but not with the corresponding control S-ODN (Figure 1 ). The level of E6AP observed by Western blot at 24 h post-lipofection varied from a two-to ®vefold reduction relative to the corresponding control S-ODN. The level of E6AP protein remained low from about 12 to 24 h post-lipofection and then gradually increased until 72 h when pre-lipofection levels were restored (Figure 2) . A ®nal concentration of 200 nM S-ODNs appeared to be optimal for lowering E6AP with minimal toxicity. Lower concentrations of S-ODNs (20 and 100 nM) only slightly decreased E6AP levels (about 70% compared to controls). Higher concentrations (500 nM) reduced E6AP to the same degree as a 200 nM dose, but showed signi®cant toxicity even with control S-ODNs (data not shown). These results argue that the reduction in E6AP is through an antisense mechanism.
Antisense inhibition of E6AP elevates p53 levels in HPV-infected cells As E6AP protein levels decreased in HeLa cells following lipofection of antisense S-ODNs, there was a concomitant increase in the level of p53 ( Figure  1 ). The inverse correlation between E6AP and p53 levels was consistent between experiments, although a 1 : 1 relative change was not always observed. A range of 3 ± 20-fold increase in p53 could be seen with a 2 ± 5-fold decrease in E6AP at the 24 h time point in HeLa cells. The increase in p53 was shows approximately one fourth the expression seen initially, and p53 expression has increased over threefold sustained only as long as E6AP levels remained low. Pre-lipofection levels of p53 were restored as E6AP levels returned to normal. A representative time course is shown in Figure 2 . Similar experiments were carried out for two other cervical cancer cell lines, HPV16 positive Caski cells and HPV18 positive C-4 II cells with the same results (data not shown). These data show that the antisense S-ODNs do not non-speci®cally reduce the levels of all cellular proteins. Further, they con®rm that E6AP plays a non-redundant role in the regulation of p53 levels in high-risk HPV-infected cells. As p53 levels increased, so did p21 levels ( Figure 1 ). Bax and Bcl2 levels were unchanged (data not shown). These results suggest that the elevated p53 seen in HeLa cells following antisense E6AP S-ODN treatment is transcriptionally active on p21.
S-ODN uptake and stability
The modulation of E6AP levels following antisense S-ODN treatment was moderate (2 ± 5-fold change) and transient (about 24 h). This led us to examine more closely the eciency of lipofection and the stability of the S-ODNs in vivo using FITC-tagged S-ODNs (Table 1) . It had previously shown that freē uorescein from degraded S-ODNs rapidly leaves the cell (Fisher et al., 1993) , so we could use thē uorescent signal to track intact S-ODNs. In HeLa cells the antisense S-ODN, FAS4, decreased E6AP to the same degree in the same time frame as the untagged counterpart (AS4). Lipofection of FAS5 had no eect on E6AP. By immuno¯uorescence it was obvious that FITC-tagged S-ODNs concentrate in the nucleus of the majority of cells during or shortly following lipofection (Figure 3 ). Fluorescein detection within the nucleus remained high until between 24 ± 48 h post-lipofection at which time it began to fade from cells. It had disappeared entirely by 72 h ( Figure  2 ). The intensity and duration of nuclear¯uorescein detection were indistinguishable between FAS4 and FAS5. These experiments demonstrate that S-ODNs concentrate in the nuclei of HeLa cells following lipofection and are degraded within 48 h.
Apoptosis in HeLa cells
Since treatment with antisense E6AP S-ODNs led to elevated p53 in HeLa, we tested cells at several time points post-lipofection for indications of apoptosis. By both¯ow cytometry and in situ labeling of fragmented DNA, we were unable to detect increased apoptosis in the antisense-treated cells. In order to better understand what level and duration of p53 expression were required to stimulate HeLa cells to apoptose, we compared relative p53 levels, duration and degree of apoptosis in HeLa lipofected with antisense E6AP S-ODNs versus HeLa electroporated with pXp53. HeLa cells were transfected with either pXp53 or pX by electroporation. Cells transfected with pX were negative for p53 by immuno¯uorescence at both 24 and 48 h postelectroporation. By immuno¯uorescence, nearly half of the cells transfected with pXp53 overexpressed p53 within 12 h. By 24 h, cells still overexpressing p53 showed normal cellular and nuclear morphology. However, by 48 h only 5% of cells were still positive for p53 upon staining. These cells almost invariably showed some feature consistent with apoptosis such as cytoplasmic blebbing or nuclear condensation (data not shown). Flow cytometry of cells transfected with either pX (at 24 and 48 h) or pXp53 (at 24 h only) showed less than 3% apoptotic cells. By 48 h nearly 20% of cells transfected with pXp53 were apoptotic (Figure 4 ). Because these cells were clearly apoptotic, we tested whether the high level p53 expression resulted in modulated levels of Bax or Bcl2. With electroporation of pXp53, as with antisense E6AP-induced p53 elevation, there was no detectable change in Bax or Bcl2 levels (data not shown).
Both the level and duration of p53 elevation by antisense E6AP S-ODNs lipofection were signi®cantly dierent from that seen by pXp53 electroporation. The antisense E6AP S-ODNs did not sustain elevation of p53 in HeLa signi®cantly beyond 48 h. Using lipofection, elevated p53 was detectable by Western blotting and not by immuno¯uorescence. Using FITC-tagged S-ODNs, it was clear that the In an eort to address the question of whether the transfected cells had been hypersensitized to DNA damage we performed the following experiment. Cells were transfected in the usual way with antisense and control S-ODNs; after 16 h of incubation transfected cells were irradiated with a single moderate dose of u.v. light (50 Jm
72
) and incubated for a further 24. Both control and antisense-transfected cells failed to survive this transfection/irradiation protocol and no dierences with respect to survival between the two populations could be detected (data not shown). Additionally, in an attempt to sustain the down-regulated levels of E6AP for longer times we attempted serial transfections of control and antisense S-ODNs; again there was substantial non-speci®c toxicity and no dierences with respect to survival between the two populations could be detected (data now shown).
Antisense inhibition of E6AP in non-HPV-infected cells
The response to antisense E6AP treatment was analysed in cells containing wild-type p53, but not infected with HPV. These included normal ®broblasts (IMR90), a colon carcinoma cell line (RKO, wt p53) and primary keratinocytes. In all of the above, antisense E6AP S-ODNs speci®cally reduced the level of E6AP protein within 24 h to a degree comparable to that observed in HPV-infected cells. In all cell types, a decrease in E6AP similar to that observed in HeLa, failed to elicit any increase in p53 (see IMR90 results in Figure 6 ). However, in IMR90 cells acutely infected with a retrovirus expressing HPV16 E6, a response similar to that in HeLa was observed (Figure 7 ). These data indicate that E6AP may not be involved in the normal degradative pathway for p53. 
Discussion
Here we provide the ®rst direct evidence that intervention in the biochemical pathway that mediates p53 ubiquitination in HPV-infected cells can alter the intracellular levels of p53. Previous work had suggested a novel enzymatic role for E6AP in p53 ubiquitination (Rolfe et al., 1995; Schener et al., 1995) , and we reasoned that intervention at the step controlled by E6AP would have a higher degree of speci®city in modulating p53 levels than intervention at some point further upstream in the ubiquitination cascade. We have shown here that low concentrations of three antisense S-ODNs targeting distinct regions of the E6AP mRNA entered the nuclei of cells. We saw a very speci®c reduction of the E6AP with the three antisense SODNs, but not with the control S-ODNs, demonstrating that the inhibition was strictly dependent on complementarity of the S-ODNs to the target mRNA. Further, we showed that intracellular levels of p53 rose upon inhibition of E6AP in HPV-infected cells. While a variety of stimuli have been shown to increase p53 levels, the elevation we observed was speci®c only to HPV-infected cells in which E6AP had been inhibited. The decrease in E6AP was transient, with the maximum decrease seen between 12 ± 24 h post-lipofection. E6AP levels gradually rose to pre-lipofection levels after 72 h. The decrease in E6AP correlated directly with the persistence of the antisense S-ODNs in the nucleus and inversely with elevated steady state p53 levels in high-risk HPVinfected cells only. This evidence con®rms a nonredundant role for E6AP in E6-dependent p53 degradation in vivo.
The elevated p53 protein present in transfected cells was transcriptionally active; we detected an increased level of p21 in HeLa cells where E6AP levels had been reduced. This demonstrates that E6 does not abrogate p53 function in vivo by suppressing its transcriptional activation of p21. There is some debate as to how necessary a transcriptionally competent form of p53 is to the induction of p53-dependent cell death. It has been shown that transcriptional activity may be required for apoptosis in some circumstances (Sabbatini et al., 1995) but not others (Caelles et al., 1994; Deng et al., 1995; Rowan et al., 1996) . Caelles and coworkers (Caelles et al., 1994) showed that somatotropic progenitor cells immortalized by SV40 and expressing a temperature sensitive p53 mutant apoptosed at the permissive temperature following DNA damage even in the presence of RNA or protein synthesis inhibitors, suggestive of a transcriptionally and translationally-independent apoptosis mechanism. Additionally, recent work based on the generation of p21-de®cient mice showed that activation of p21 by p53 was not necessary for a normal apoptotic response in cells derived from these mice (Brugarolas et al., 1995; Deng et al., 1995) .
Other candidate target genes that may be up-or down-regulated by p53 include bax and bcl2 (Miyashita and Reed, 1995) these genes can mediate apoptosis in certain circumstances (Hockenbery et al., 1990; Steller, 1995) . In our experiments using antisense E6AP S-ODNs bax and bcl2 levels were unaltered by elevated p53. Interestingly, even in the HeLa cells that are clearly undergoing apoptosis following electroporation of pXp53, there was no change in the levels of these apoptosis-modulating proteins (data not shown). Recent work from Canman and colleagues (1995) also failed to correlate bax and bcl2 levels with p53-induced apoptosis.
We were unable to detect apoptosis in the antisensetransfected cell population. This inability to detect apoptosis may be due in part to a failure to sustain elevated levels of p53 beyond 24 h. The expression of p53 peaked between 16 ± 24 h post-lipofection and fell thereafter as normal levels of E6AP were restored between 48 ± 72 h. Even with marked overexpression of p53 in plasmid electroporation experiments, apoptosis was not apparent in a 12 ± 24 h time frame; it became detectable 36 ± 48 h post-transfection when p53 levels were still very high. In contrast, by 36 ± 48 h postlipofection of the E6AP antisense S-ODNs, p53 had almost returned to pre-lipofection levels, and no apoptosis was evident. Findings in other experimental systems are broadly in agreement with this; the ®rst indications of p53-mediated apoptosis usually appear around 24 h after restoration of wild-type p53 function, often requiring 2 ± 3 days to become obvious (Lowe et al., 1993a; Sabbatini et al., 1995; Shaw et al., 1992; Wu and Levine, 1994) .
There is also a clear threshold component to p53-dependent apoptosis. A p53 gene-dose dependent eect on apoptosis has been observed (Clarke et al., 1993; Lowe et al., 1993a,b transfected HeLa cells compared to mock-transfected cells; the levels reached were similar to the antisense S-ODN transfected cells. This presumably re¯ects thè DNA damaging' nature of plasmid transfections and argues that this modest increase in p53 levels is insucient to induce apoptosis. Even if we were able to sustain suppression of E6AP activity, it is possible that release from accelerated degradation alone may not be sucient to elevate p53 to levels required to initiate apoptosis. The normal degradation pathway and negative feedback mechanisms may still be intact, maintaining p53 levels relatively low. Therefore, as in other Rb-de®cient cells, an additional signal, such as ionizing radiation, or insult with an anticancer agent may be required (Caelles et al., 1994; Clarke et al., 1993; Lowe et al., 1993a,b) to stimulate further elevation of p53 and drive apoptosis. In our initial experiments addressing this point we could not detect dierences between control and antisense transfected cells due to the substantial non-speci®c toxicity of the S-ODNs. Primary keratinocytes and ®broblasts did not show elevated p53 levels following transfection of antisense E6AP S-ODNs although intracellular E6AP levels did fall. This suggests that E6AP may not be the E3 involved in p53 degradation in non-HPV-infected cells or that the kinetics of the degradation pathway are quite dierent. However, ®broblasts acutely infected with a retrovirus containing E6 did respond to decreased E6AP levels by elevating p53. This indicates that in HPV-infected cells, the E6 protein enhances the degradation of p53 by recruiting an E3 not normally involved in the ubiquitination of p53. There is abundant indirect evidence for involvement of the ubiquitin-dependent proteolytic pathway in the turnover of p53 in non-HPV-infected cells. The peptide aldehyde inhibitor of the proteasome Z-LLL, when exposed to a number of dierent cell lines (RKO, HeLa, IMR90; Beer-Romero, unpublished results) led to a rapid accumulation of p53. Additionally, growth of mouse cells with a ts E1 mutation (Chowdary et al., 1994) at their non-permissive temperature led to an increase in p53 levels, as result of p53 stabilization. Recently, ubiquitin-p53 conjugates were detected in cells treated with proteasome inhibitors (Maki et al., 1996) . The speci®c components of the ubiquitin proteolytic pathway involved in p53 turnover in non-HPV-infected cells still await identi®cation.
In summary, our results validate the concept that disruption of the E3 function in a ubiquitin-mediated proteolysis pathway in vivo can result in the speci®c elevation of the protein substrate. Using antisense SODNs, we have con®rmed the essential role of E6AP in the degradation of wild-type p53 in HPV-infected cells and suggest that normal cells may use a dierent E3 to degrade p53. There may be therapeutic potential for pharmaceutical agents that inhibit the ubiquitinmediated turnover of wild-type p53. Such agents would be expected to induce a G 1 arrest in most cells where the Rb pathway is intact and increase susceptibility to cell death by lowering the threshold for apoptosis in cells where the Rb pathway is compromised Morgenbesser et al., 1994; White, 1994) . We propose that by targeting E6AP with more stable antisense S-ODNs or with small molecule inhibitors, one should be able to increase susceptibility to apoptosis in cervical cancer cells infected with highrisk HPV. Further analysis of the systems that regulate p53 levels in vivo and the eects of altering these systems in dierent genetic backgrounds will contribute to our understanding of tumor progression and the design and evaluation of novel chemotherapeutic agents.
Materials and methods
Cell culture
IMR90 (normal human lung ®broblasts) and cervical carcinoma cell lines, HeLa, C-4 II and Caski were purchased from the American Type Culture Collection. Both HeLa and C4II have integrated HPV-18 DNA and Caski contains HPV-16 DNA (Yee et al., 1985) . IMR90 acutely infected with a retrovirus containing HPV 16 E6 (Shay et al., 1993) were a gift from JW Shay (University of Texas Southwestern, Dallas, TX). Normal human epidermal keratinocytes were obtained from Clonetics and grown in Keratinocyte Growth Medium supplemented with bovine pituitary extract and trypsinized using ReagentPack (all from Clonetics). All other cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 mg/ml streptomycin. All cells were grown at 378C in an humidi®ed chamber with 5% CO 2 .
S-ODNs
The three antisense S-ODNs were designed to target distinct regions of E6AP (Table 1) . Control S-ODNs were chosen to be the reverse sequence (3'-5') of the antisense S-ODN to assure identical nucleotide content and minimize dierences potentially attributable to nucleic acid context. S-ODNs identical to AS4 and AS5 were synthesized with uorescein (FITC) on the 5' end in order to assess uptake and stability. The FITC-tagged versions of AS4 and AS5 were designated FAS4 and FAS5, respectively (Table 1) . All S-ODNs were synthesized by Oligos Etc.
Lipofection
Lipofections were carried out using lipofection and Opti-MEM (GibcoBRL). Cells were grown to 50% con¯uence on 100 mm tissue culture plates, rinsed twice in serum free medium and overlaid with the lipofection mix (8 ml Opti-MEM, 52.8 ml lipofectin, 8 ml of 200 mM stock S-ODNs). In experiments where dierent ®nal concentrations of SODNs were used, the amount of lipofectin was adjusted proportionally. Cells were incubated in the presence of the lipofectin mix for 5 h. Following incubation, the lipofection medium was replaced with normal growth medium containing serum, and cells were returned to 378C. Cells were harvested at dierent times post-lipofection for analysis.
Electroporation
The cytomegalovirus expression vectors pX and pXp53 used herein were previously described (Rolfe et al., 1995) . For each plasmid to be transfected, 2610 6 log phase HeLa cells were trypsinized, washed twice in cold PBS and pelleted. Each pellet was resuspended in 10 ml cold 106PBS, 50 ml cold ddH 2 O and 40 ml (20 mg) of the respective plasmid DNA and incubated on ice for 10 min. After a single pulse of 280 volts and 125 mF, cells were immediately resuspended in complete DMEM, plated into two 100 mm tissue culture dishes with several coverslips and incubated for 12 ± 48 h at 378C.
Apoptosis detection
The ApopTag in situ apoptosis detection kit (Oncor) was used to¯uorescein-lable 3'-OH DNA ends generated by DNA fragmentation. Flow cytometry was employed to determine what fraction of the total culture population was apoptotic.
Gel electrophoresis and immunoblotting
Cells were lysed in 50 mM Tris-HCl, pH 7.5, 0.25 M NaCl, 1 mM EDTA, 50 mM NaF, 0.1 mM Na 3 VO 4 , 1 mM DLdithiothreitol, 1 mg/ml of leupeptin, 10 mg/ml of soybean trypsin inhibitor, 1 mg/ml of aprotinin, 10 mg/ml of L-1 chlor-3-(4-tosylamido)-4-phenyl-2-butanon, 10 mg/ml of L-1 chlor-3-(4-tosylamido)-7-amino-2-heptanon-hydrochloride, 0.1 mM phenyl-methyl sulfonyl¯uoride and 1% triton-X100 for 30 min on ice. Crude cell lysates (50 mg/ lane) were separated by SDS-polyacrylamide gel electrophoresis on 4 ± 20% Tris-glycine gels (NOVEX) and transferred onto nitrocellulose membranes. Blots were blocked in 5% nonfat dry milk in PBS, 0.1% Tween-20 and exposed to primary antibodies. Proteins were visualized using horseradish peroxidase linked sheep antimouse or donkey anti-rabbit secondary antibodies (Amersham Life Science) and chemiluminescence reagents (Renaissance, Dupont NEN).
Antibodies
Human monoclonal p53 antibody, Mab DO-1 was purchased from Oncogene Science. The p21 antibody was a gift from David Beach (Howard Hughes Laboratory, Cold Spring Harbor). Bax antibody (N-20) and bcl-2 (100) antibody were purchased from Santa Cruz Biotechnology, Inc. The E6AP antibody was raised to the C-terminal peptide of E6AP plus an N-terminal cysteine (CAKGFGML), synthesized by Multiple Peptide Systems (San Diego, CA). The peptide was coupled to keyhole limpet hemocyanin and injected into rabbits by Pocono Rabbit Farm (Canadensis, PA). The third bleed was anity-puri®ed on cyanogen bromide-activated Sepharose 4B (Pharmacia Biotech) according to the manufacturer's protocol.
Densitometry
The relative intensity of bands on X-ray ®lm was determined using Geldoc 1000 hardware and Molecular Analyst software (Bio-Rad Laboratories).
Immuno¯uorescence
HeLa cells grown on glass coverslips to 40 ± 60% density were lipofected as described above with FITC-tagged SODNs. At dierent times post-lipofection, cells were ®xed, revealed with p53 monoclonal antibody and photographed as previously described (Rolfe et al., 1995) .
Flow cytometry
Cells were harvested, washed in cold PBS, ®xed in 70% ethanol, and stained with propidium iodide. Flow cytometric analysis was performed using a FACScan cytometer (Becton Dickinson).
